Anti-HIV-1 gp41 Recombinant Antibody (4E10-IgG3) (CAT#: MRO-025LC)

Figure 1. Inhibition of HIV-1 infection in primary macrophages. All three MAbs were IgG; 4E10 served as a positive control, and the nonneutralizing anti-HIV-1 Mab A32 was used as a negative control.

Zhu, Z., Qin, H. R., Chen, W., Zhao, Q., Shen, X., Schutte, R., ... & Fouda, G. G. (2011). Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. Journal of virology, 85(21), 11401-11408.

Figure 2. Antibody-dependent cell-mediated viral inhibition (ADCVI) of 2F5 and 4E10 in comparison to b12. Supernatant was collected and assayed for p27 by ELISA to measure viral inhibition.

Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., ... & Burton, D. R. (2010). Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. Journal of virology, 84(3), 1302-1313.

Figure 1 Binding of 2F5 and 4E10 to peptides 2030, 2031, and gp160. Serial twofold dilutions of peptides were coated overnight on ELISA plates before incubation with constant amounts of 4E10 or 2F5 (100 ng/ml).